Head-to-head evidence
SHR-3167 vs THDB0206
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
SHR-3167
Developed by Jiangsu Hengrui Pharmaceuticals
NCT06688123 · Phase 2 · completed
The study used randomization and an active insulin glargine comparator in 275 participants, but it was open-label rather than blinded. Its primary endpoint was change in HbA1c, a surrogate measure, and no results are currently available to show whether the primary comparison was met.
Next expected readout: December 2026 · NCT07472725 (registry estimate)
THDB0206
Developed by Tonghua Dongbao Pharmaceutical
NCT05834868 · Phase 3 · completed
The study was randomized and actively controlled with insulin lispro, but it was open-label and used change in HbA1c as its primary, surrogate endpoint rather than a hard clinical outcome. No primary endpoint results have been posted, so whether THDB0206 met its objective is unknown.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SHR-3167's landscape · THDB0206's landscape